Maria Rebelo is interested in investigating novel tools to fight antimalarial drug resistance. Maria completed her PhD in 2017, during which she developed a novel drug assay based on the flow cytometric detection of haemozoin. Currently, Maria is investigating the parasite response to antimalarial drug candidates in malaria volunteer infection studies. She was involved in the development of a novel artemisinin-resistant induced blood stage malaria model. More recently, she employed an ex vivo approach to determine parasite viability after drug treatment and to elucidate parasite clearance and recrudescence observed in humans. In 2018, Maria was awarded with an ACREME Seed Grant to develop a novel humanised mouse model of artemisinin-resistant malaria, to be used as pre-clinical screening tool to select the best drugs to progress to clinical development in humans.